Sudha Rathod

The aim of the present study is to minimize the local gastrointestinal irritation which is one of the major side effects of Piroxicam (PR) by the formulation  oral  stomach specific in situ gelling emulsion ingestion by kinetic control of drug release. Material and method: In situ emulgel were prepared by using castor oil as oil phase ,tween 80 and span 80 as emulsifiers, sodium alginate was used as gelling agent,  xanthan gum was used as release retardant ,calcium carbonate was used as cross linking agent, pH triggered ionic gelation is the mechanism involved in the present study. Various evaluation tests were done for all formulations Results: Formulation F9 containing 2.5% of sodium alginate, 2 % of CaCO3, 1 % of sodium bicarbonate and 0.8% of Xanthan gum was selected as optimized batch based on  Q10 86.02±0.17 %, floating time 122.15±2.47 sec and drug content 91.86±1.02 %. The release pattern of drug was found to follow Korsemeyer and Highuchi model. The DSC study exposed that there was no incompatibility. Pharmacodynamic study on Wistar rats were showed significant anti inflammatory and anti arthritic activity of the optimized formulation. Further, in vivo toxicity studies carried out in wistar rats revealed no signs of gastric ulceration upon prolonged dosing. Conclusion: It was concluded that the oral stomach specific In situ gelling emulsion of piroxicam could be an effective dosage form which minimize the gastric irritation by coating drug with castor oil and remains buoyant and control the drug release for 24hrs.

Buccal administration of drugs provides a convenient route of administration for both systemic and local drug actions. However, the preferred site for retentive oral transmucosal delivery systems and for sustained- and controlled-release delivery devices is the buccal mucosa, mainly because of the differences in permeability characteristics between the two regions and the buccal mucosa’s expanse of smooth and relatively immobile mucosa. The buccal mucosa offers excellent possibilities for the (long-term) delivery of suitable drugs, especially for metabolically unstable drugs, such as peptides. In the development of these buccal drug delivery systems, mucoadhesion of the device is a key element. Mucoadhesive polymers have been utilized in many different dosage forms in efforts to achieve systemic delivery of drugs through the buccal mucosa. Buccoadhesive drug delivery is relatively new drug delivery strategy; in this traditional polymers are replaced by novel bioadhesive polymers such as thiomers & lectins etc. to overcome limitation of traditional polymer.